Cancer name Skin Cutaneous Melanoma
Cancer Type SKCM
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment Selinexor
Drugstatus Approved, Investigational
Drugbank ID DB11942
Checkpoints NA
Signature Type Protein
Signature PD-1
Official Symbol PDCD1
Mode of action TRAN_D_UP
Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental NA
Description To understand how XPO1 inhibition affects the expression of checkpoint molecules on immune cells, leukocytes from healthy donors were cultured in vitro with selinexor and changes in gene expression of the clinically relevant T cell checkpoint molecules PDCD1 (encoding PD-1), CD274 (encoding PD-L1), and CTLA4 (encoding CTLA4) were measured by qPCR. At 24 hours, selinexor significantly increased the expression of both PDCD1 and CTLA4 (2.2 fold and 2.8 fold, respectively, p<0.01)
PMID 28148715
Title The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors